ValiRx PLC Hardman Research: GeneICE and VAL101 progress
September 13 2017 - 4:34AM
RNS Non-Regulatory
TIDMVAL
ValiRx PLC
13 September 2017
Hardman Research: GeneICE and VAL101 progress
GeneICE and VAL101 progress: ValiRx is a clinical-stage
biopharmaceutical company focused on the development of
therapeutics for the treatment of cancer, associated biomarkers and
companion diagnostics. The company's two leading assets are in
clinical trials: VAL201 (Phase I/II) - a peptide for advanced
prostate cancer and potential to treat other hormone- induced
indications; and VAL401 (Phase II) - a novel reformulation of
risperidone, in trials for lung cancer. Optimisation of the
manufacturing process for its GeneICE technology platform has
enabled the development of a commercially viable process and
acceleration of the development of VAL101 towards the clinic.
Please click here for the full report:
http://www.hardmanandco.com/docs/default-source/company-docs/valirx-plc-documents/13.09.17-geneice-and-val101-progress.pdf
To contact us: Analysts:
Hardman & Co Dr Martin Hall mh@hardmanandco.com
35 New Broad Street Dr Dorothea Hill dmh@hardmanandco.com
London Dr Gregoire Pave gp@hardmanabdco.com
EC2M 1NH Telephone: +44 20 7194 7622
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAVXLBFDKFXBBL
(END) Dow Jones Newswires
September 13, 2017 04:34 ET (08:34 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024